Answers are grounded in this paper and cite their sources.
Real-world analysis shows blinatumomab nonresponse correlates with worse outcomes in relapsed/refractory B-ALL, indicating treatment challenges.
In a real-world analysis of brexucabtagene autoleucel (brexu-cel) recipients with relapsed/refractory B-ALL (n = 278), lack of response to prior blinatumomab correlates with significantly worse post CAR-T outcomes.
No takes yet. Share an insight, caveat, or question.
Srinagesh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: